The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A real-world analysis of the effectiveness of pembrolizumab by type of associated treatment in patients with metastatic cervical cancer: Added value of bevacizumab.
 
Alberto Farolfi
Honoraria - AstraZeneca/Merck; GlaxoSmithKline/Tesaro; Janssen; MSD/Merck
Consulting or Advisory Role - AstraZeneca/Merck; GlaxoSmithKline; Janssen
Travel, Accommodations, Expenses - AstraZeneca/Merck; Bayer; Ipsen; Janssen; MSD
 
Chiara Casadei
No Relationships to Disclose
 
Caterina Gianni
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Eleonora Paoletti
No Relationships to Disclose
 
Michela Palleschi
Honoraria - Daiichi Sankyo; Gilead Sciences; Novartis
Travel, Accommodations, Expenses - AstraZeneca/Merck; Lilly; Novartis
 
Daniela Montanari
No Relationships to Disclose
 
Giulia Miserocchi
No Relationships to Disclose
 
Gema Hernández
Employment - Trinetx
 
Nicola Gentili
No Relationships to Disclose
 
Marita Mariotti
No Relationships to Disclose
 
Sara Testoni
No Relationships to Disclose
 
Giandomenico Di Menna
No Relationships to Disclose
 
Francesca Rusconi
Employment - Trinetx
 
Alice Andalò
No Relationships to Disclose
 
Filippo Merloni
No Relationships to Disclose
 
Marianna Sirico
No Relationships to Disclose
 
Roberta Maltoni
No Relationships to Disclose
 
Lorenzo Cecconetto
No Relationships to Disclose
 
Samanta Sarti
No Relationships to Disclose
 
Antonino Musolino
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Eisai Europe; Lilly; Novartis; Seagen
Research Funding - Lilly; Roche (Inst)
Travel, Accommodations, Expenses - Pfizer